A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression

Published: 05-12-2022
Last updated: 10-01-2025

This study has been transitioned to CTIS with ID 2023-505455-44-00 check the CTIS register for the current data. Part 1 (phase 1b)Primary:• To observe the safety and tolerability of bemarituzumabSecondary:• To evaluate preliminary antitumor activity...

Ethical review	Approved WMO
Status	Recruiting
Health condition type	Other condition
Study type	Interventional

Summary

ID

NL-OMON55987

Source
ToetsingOnline

Brief title
20210104 - FORTITUDE-301

Condition

- Other condition
- Benign neoplasms gastrointestinal
- Ovarian and fallopian tube disorders

Synonym
cancer, malignant tumor

Health condition

basketstudie: meerdere indicaties, zie inclusie criteria

Research involving
Human

Sponsors and support

Primary sponsor: Amgen
Source(s) of monetary or material Support: Amgen

Intervention

Keyword: Basket study, Bemarituzumab, FGFR2b overexpression, Solid tumours

Outcome measures

Primary outcome

Part 1 (phase 1b)

• Dose-limiting toxicities (DLTs), treatment-emergent adverse events,

treatment-related adverse events, and clinically significant changes in vital

signs, visual acuity, and clinical laboratory tests

Part 2 (phase 2)

• OR

Secondary outcome

Part 1 (phase 1b)

• Objective response (OR) (OR = complete response [CR] + partial response

[PR]), measured by computed tomography (CT) or magnetic resonance imaging (MRI)

as determined by investigator per Response Evaluation Criteria in Solid Tumors

version 1.1 (RECIST v1.1)

• Disease control (DC) (CR, PR, or stable disease [SD])

• Duration of response (DOR), defined as the time from first documentation of

objective response (as determined by investigator per RECIST v1.1) until the first documentation of disease progression or death due to any cause, whichever occurs first. Only subjects who have achieved objective response will be evaluated for DOR. Duration of response will be censored at the last evaluable post-baseline tumor assessment prior to subsequent anticancer therapy.

• Time to response (TTR)

Part 2 (phase 2)

• OR

• DC

• DOR

• TTR

• PFS

• OS

• Treatment-emergent adverse events, treatment-related adverse events, and clinically significant changes in vital signs, visual acuity, and clinical laboratory tests

Study description

Background summary

Inhibition of FGFR2b signaling may be an effective mechanism of action for multiple cancer indications and forms the basis for this study. Alterations in the FGF/FGFR2 signaling pathway have been reported in the literature for multiple tumor types. Data from The Cancer Genome Atlas (TCGA), report detection of FGFR2 overexpression by mRNA is common amongst epithelial cancers. Among high expressing cancers are cholangiocarcinoma (93.3%), ovarian

cancer (78.8%), pancreatic (33.9%), triple negative breast cancer (41.8%), head and neck carcinoma (57.5%), esophageal squamous cell carcinoma (45.7%), endometrial carcinoma (46.7%), cervical cancer (29.4%), and colorectal cancer (12.9%). Evaluation of bemarituzumab in subjects with FGFR2b overexpressing tumors may improve the outcome for these subjects by providing targeted inhibition of tumor growth signaling.

Study objective

This study has been transitioned to CTIS with ID 2023-505455-44-00 check the CTIS register for the current data.

Part 1 (phase 1b)
Primary:
• To observe the safety and tolerability of bemarituzumab

Secondary:
• To evaluate preliminary antitumor activity
• Characterize the pharmacokinetics (PK) of bemarituzumab

Part 2 (phase 2)
Primary:
• To evaluate preliminary antitumor activity

Secondary:
• To evaluate other measures of preliminary antitumor activity
• To evaluate the safety and tolerability of bemarituzumab
• Characterize the PK of bemarituzumab monotherapy

Study design

This is a phase 1b/2, open-label, multicenter exploratory, basket study to evaluate the efficacy and safety of bemarituzumab monotherapy in subjects across multiple primary epithelial solid tumors with centrally determined FGFR2b overexpression and relapsed/refractory unresectable and/or metastatic disease.
This study consists of a pre-screening period to collect tumor tissue for centralized FGFR2b testing, a 28 day screening period, a treatment period, a safety follow-up (SFU) period, and a long term follow up (LTFU) period. Subjects who discontinue bemarituzumab will undergo a SFU visit 28 (+ 3) days after the last dose of study treatment. In addition, subjects will undergo LTFU for survival approximately every 3 months (± 1 month) after the SFU visit for up to 2 years from the first dose of bemarituzumab. Subjects will receive treatment until disease progression, unacceptable toxicity, subject request, or death (whichever occurs first).

Intervention

Bemarituzumab will be administered as a short-term IV infusion every 14 days (in a cycle of 14 days) as monotherapy.

Study burden and risks

Please refer to section E2 and E9.

Contacts

Public
Amgen

Minervum 7061
Breda 4817 ZK
NL
Scientific
Amgen

Minervum 7061
Breda 4817 ZK
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

109 Histologically or cytologically confirmed cancer, advanced or metastatic,

refractory or relapsed after at least 1 prior standard treatment:
o Head and neck squamous cell carcinoma >= 1 line of therapy
o Triple-negative breast cancer >= 2 lines of therapy
o Intrahepatic cholangiocarcinoma >= 1 line of therapy
o Lung adenocarcinoma: at least platinum-based chemotherapy, checkpoint inhibitor, and targeted therapy (ie, if molecular testing has identified targetable mutations in EGFR, ALK, etc)
o Ovarian epithelial carcinoma, including fallopian tube cancers and primary peritoneal cancers, >= 1 line of therapy (platinum-resistant)
o Endometrial adenocarcinoma >= 1 line of therapy
o Cervical carcinoma >= 1 line of therapy
o Other solid tumours >= 1 line of therapy
104 Disease that is unresectable, locally advanced, or metastatic (not amenable to curative therapy)
105 Tumor overexpresses FGFR2b as determined by centrally performed IHC testing
106 Measurable disease per RECIST v1.1
107 Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
110 Adequate hematologic and organ function, defined as follows:
• Absolute neutrophil count >= 1.5 x 109/L
• Platelet count >= 100 x 109/L
• Hemoglobin >= 9 g/dL
• AST and ALT < 3 x upper limit of Normal [ULN] (or < 5 x ULN in case of liver involvement). Total bilirubin < 1.5 x ULN (or < 2 x ULN in case of liver involvement or Gilbert*s disease)

For more details please see section 5.1 Inclusion Criteria within the protocol.

Exclusion criteria

201 Untreated or symptomatic central nervous system (CNS) metastases or leptomeningeal disease
• Subjects with asymptomatic CNS metastases are eligible if clinically stable for at least 4 weeks and do not require intervention (including use of corticosteroids)
• Subjects with treated brain metastases are eligible provided the following criteria are met:
- Definitive therapy was completed at least 2 weeks prior to the first planned dose of study treatment (stereotactic radiosurgery at least 7 days prior to first planned dose of study treatment)
- At least 7 days prior to first planned dose of study treatment: any CNS disease is clinically stable, subject is off steroids for CNS disease (unless steroids are indicated for a reason unrelated to CNS disease), and subject is off or on stable doses of anti-epileptic drugs
202 Other solid tumor cohort excludes primary tumors of the CNS, squamous non small cell lung cancer, gastric adenocarcinoma, and gastroesophageal junction

adenocarcinoma
203 History of other malignancy within the past 2 years, with the following exceptions:
• curatively treated non-melanoma skin malignancy
• cervical cancer in situ
• curatively treated uterine cancer stage I
• curatively treated ductal or lobular breast carcinoma in situ and not currently receiving any systemic therapy
• localized prostate cancer that has been treated surgically with curative intent and presumed cured
205 Active infection requiring systemic treatment or any uncontrolled infection within 14 days prior to first dose of study treatment

For more details please see section 5.2 exclusion Criteria within the protocol.

Study design

Design

Study type: Interventional

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruiting
Start date (anticipated):	03-04-2023
Enrollment:	11
Type:	Actual

Medical products/devices used

Generic name:	VENTANA FGFR2b (FPR2 D) Robust Prototype Assay
Registration:	No
Product type:	Medicine
Brand name:	Bemarituzumab
Generic name:	Bemarituzumab

Ethics review

Approved WMO Date:	05-12-2022
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	21-12-2022
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	16-01-2023
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	14-08-2023
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	27-09-2023
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	11-12-2023
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	01-02-2024
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO	

Date:	25-03-2024
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	28-03-2024
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EU-CTR	CTIS2023-505455-44-00
EudraCT	EUCTR2021-006386-38-NL
ClinicalTrials.gov	NCT-nummernognietbekend.Hetnummervolgt
CCMO	NL80395.000.22